Three-year outcomes of cranial nerve stimulation for obstructive sleep apnea

• Verfasst von: Woodson, B. Tucker [VerfasserIn]
• Verfasst von: Maurer, Joachim T. [VerfasserIn]
• Titel: Three-year outcomes of cranial nerve stimulation for obstructive sleep apnea
• Titelzusatz: the STAR trial
• Verf.angabe: B. Tucker Woodson, MD, Ryan J. Soose, MD, M. Boyd Gillespie, MD, Kingman P. Strohl, MD, Joachim T. Maurer MD, Nico de Vries, MD, David L. Steward, MD, Jonathan Z. Baskin, MD, M. Safwan Badr, MD, Ho-sheng Lin, MD, Tapan A. Padhya, MD, Sam Mickelson, MD, W. McDowell Anderson, MD, Olivier M. Vanderveken, MD, PhD, and Patrick J. Strollo Jr, MD, on behalf of STAR Trial Investigators
• Jahr: 2016
• Jahr des Originals: 2015
• Umfang: 8 S.
• Fussnoten: Gesehen am 23.01.2019 ; First Published November 17, 2015
• Titel Quelle: Enthalten in: Otolaryngology - head and neck surgery
• Ort Quelle: Oxford [u.a.] : Wiley-Blackwell, 1978
• Jahr Quelle: 2016
• Band/Heft Quelle: 154(2016), 1, Seite 181-188
• ISSN Quelle: 1097-6817
• DOI: doi:10.1177/0194599815616618
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1586504126

Abstract

Objective: To describe the 36-month clinical and polysomnography (PSG) outcomes in an obstructive sleep apnea (OSA) cohort treated with hypoglossal cranial nerve upper airway stimulation (UAS). Study Design: A multicenter prospective cohort study. Setting: Industry-supported multicenter academic and clinical setting. Subjects: Participants (n = 116) at 36 months from a cohort of 126 implanted participants. Methods: Participants were enrolled in a prospective phase III trial evaluating the efficacy of UAS for moderated to severe OSA. Prospective outcomes included apnea-hypopnea index, oxygen desaturation index, other PSG measures, self-reported measures of sleepiness, sleep-related quality of life, and snoring. Results: Of 126 enrolled participants, 116 (92%) completed 36-month follow-up evaluation per protocol; 98 participants additionally agreed to a voluntary 36-month PSG. Self-report daily device usage was 81%. In the PSG group, 74% met the a priori definition of success with the primary outcomes of apnea-hypopnea index, reduced from the median value of 28.2 events per hour at baseline to 8.7 and 6.2 at 12 and 36 months, respectively. Similarly, self-reported outcomes improved from baseline to 12 months and were maintained at 36 months. Soft or no snoring reported by bed partner increased from 17% at baseline to 80% at 36 months. Serious device-related adverse events were rare, with 1 elective device explantation from 12 to 36 months. Conclusion: Long-term 3-year improvements in objective respiratory and subjective quality-of-life outcome measures are maintained. Adverse events are uncommon. UAS is a successful and appropriate long-term treatment for individuals with moderate to severe OSA.